Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II cli… Read more
Revance Therapeutics, Inc. - Asset Resilience Ratio
Revance Therapeutics, Inc. (RVNC) has an Asset Resilience Ratio of 27.19% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2023)
This chart shows how Revance Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Revance Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $125.49 Million | 27.19% |
| Total Liquid Assets | $125.49 Million | 27.19% |
Asset Resilience Insights
- Very High Liquidity: Revance Therapeutics, Inc. maintains exceptional liquid asset reserves at 27.19% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Revance Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Revance Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Revance Therapeutics, Inc. (2011–2023)
The table below shows the annual Asset Resilience Ratio data for Revance Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 24.37% | $116.59 Million | $478.45 Million | -15.46pp |
| 2022-12-31 | 39.83% | $231.74 Million | $581.90 Million | +18.28pp |
| 2021-12-31 | 21.55% | $114.45 Million | $531.16 Million | +7.25pp |
| 2020-12-31 | 14.29% | $102.95 Million | $720.22 Million | -20.66pp |
| 2019-12-31 | 34.96% | $118.95 Million | $340.29 Million | -10.35pp |
| 2018-12-31 | 45.31% | $102.56 Million | $226.35 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $295.70 Million | -- |
| 2016-12-31 | 59.71% | $122.03 Million | $204.36 Million | +41.33pp |
| 2015-12-31 | 18.38% | $50.69 Million | $275.82 Million | +18.34pp |
| 2014-12-31 | 0.04% | $75.00K | $192.47 Million | -0.29pp |
| 2013-12-31 | 0.33% | $75.00K | $22.64 Million | -0.23pp |
| 2012-12-31 | 0.56% | $75.00K | $13.42 Million | +0.37pp |
| 2011-12-31 | 0.19% | $75.00K | $39.93 Million | -- |